ARCH Venture Management, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001274403

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 12 positions · Total reported value $1.10B · Top-10 concentration 99.3% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.5% · 3 new · 1 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +17.4% · vs SPY +2.6% · Prev Value $677.09M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, ARCH Venture Management, LLC disclosed 12 equity positions with a combined reported value of $1.10B. The filing implies a focused portfolio: its ten largest positions account for 99.3% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were PBLS ($175.52M), BEAM ($155.77M), RAPP ($155.38M). By sector, the heaviest allocations are Health Care 99.2%, Industrials 0.8%.

Versus the prior quarter, ARCH Venture Management, LLC opened 3 new positions, trimmed 1 and fully exited 1, a turnover rate of 38.5% of positions. The portfolio's overlap with the prior quarter was 69% of names.

The largest new positions opened in Q2 2026 were PBLS ($175.52M), SPTX ($136.60M), BOLD ($6.74M).

Of the 1 positions fully exited versus the prior quarter, the largest were QTTB ($2.06M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • PBLS PARABILIS MEDICINES INC · $175.52M
  • SPTX SEAPORT THERAPEUTICS INC · $136.60M
  • BOLD BOUNDLESS BIO INC · $6.74M

Fully Exited (vs previous quarter)

  • QTTB Q32 BIO INC · prev qtr: $2.06M

Insider Transactions (Form 4)

Latest ARCH Venture Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

ARCH Venture Management, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 12 positions worth $1.10B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 12 positions · $1.10B reported value (Q2 2026)
  • Top 10 holdings = 99.3% of reported value
  • Largest position: PBLS (PARABILIS MEDICINES INC) at 16.0%
  • Average position size: $91.69M

Sector Tilt

  • Health Care 99.2%
  • Industrials 0.8%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 new, 1 reduced, 1 exited
  • 8 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautiously optimistic view with a focus on biotechnology and healthcare sectors, indicating a belief in the long-term potential of these areas. The slight reduction in VIR, despite its high share value, suggests a possible concern over market or company-specific risks in that sector. 2. Key Moves: - New Positions: Three new additions (PBLS, SPTX, and TXG) signal a proactive approach to discovering and investing in potentially high-growth companies. - Hold Positions: The fund maintained positions in the majority of its holdings, showing confidence in their current performance or potential. - Reduction: A reduction in VIR shares by 1.7% might reflect a conservative move in response to potential market or company-specific concerns. 3. Portfolio Structure: The portfolio seems to be active in nature, with a strong sector bias towards healthcare and biotechnology. The fund displays a moderate risk appetite, as indicated by the relatively small allocation to TXG and the slight reduction in VIR. There is a balance between maintaining existing positions and seeking out new opportunities. 4. Per-Holding One-Liner: - PBLS: PARABILIS MEDICINES INC COM – Developing treatments for genetic diseases. - BEAM: BEAM THERAPEUTICS INC – Focused on developing treatments for chronic diseases. - RAPP: RAPPORT THERAPEUTICS INC – Developing novel cancer treatments. - SPTX: SEAPORT THERAPEUTICS INC – Engaged in drug discovery and development for neurological diseases. - ERAS: ERASCA INC – Specializes in developing therapies for rare and orphan diseases. - VIR: VIR BIOTECHNOLOGY INC – A clinical-stage biotechnology company. - MAZE: MAZE THERAPEUTICS INCORPORATED – Developing novel therapies for rare genetic disorders. - LYEL: LYELL IMMUNOPHARMA INC – Focused on developing therapies for oncology and inflammatory diseases. - GENB: GENERATE BIOMEDICINES INC – Engaged in the discovery and development of novel therapies. - TXG: 10X GENOMICS INC – A genomic engineering and synthetic biology company. 5. One-Sentence Style Summary: ARCH Venture Management, LLC maintains an active, healthcare-focused portfolio, cautiously diversifying with new additions and holding steady in existing biotech investments, reflecting a balanced approach to risk and potential growth.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 99.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 6.41M $175.52M 15.95%
15.95%
New
2 4.54M $155.77M 14.16%
14.16%
Hold
3 3.73M $155.38M 14.12%
14.12%
Hold
4 6.29M $136.60M 12.41%
12.41%
New
5 7.09M $129.92M 11.81%
11.81%
Hold
6 12.69M $129.35M 11.76%
11.76%
Reduce
7 4.12M $122.98M 11.18%
11.18%
Hold
8 3.25M $45.53M 4.14%
4.14%
Hold
9 1.94M $32.80M 2.98%
2.98%
Hold
10 217.83K $8.35M 0.76%
0.76%
Hold
11 2.69M $6.74M 0.61%
0.61%
New
12 8.06M $1.33M 0.12%
0.12%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 80% R 80% F1 80% (modelled on 2026-Q1; 8/10 hit)

Historical Backtest (10 quarters)

Avg precision 90% · recall 87% · F1 88% · avg rank error 2.1 · Top-10 turnover 10%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 86% 75% 80% RVMD · VERV · ERAS · GOSS · DNLI · UNBX · OMIC VERV · ERAS · GOSS · DNLI · QTTB · CERO · OMIC · UNBX
2024-Q2 88% 78% 82% VERV · ERAS · GOSS · DNLI · QTTB · CERO · OMIC · UNBX BEAM · RAPP · ERAS · VERV · GOSS · QTTB · UNBX · OMIC · CERO
2024-Q3 100% 100% 100% BEAM · RAPP · ERAS · VERV · GOSS · QTTB · UNBX · OMIC · CERO BEAM · RAPP · ERAS · QTTB · VERV · GOSS · OMIC · UNBX · CERO
2024-Q4 100% 100% 100% BEAM · RAPP · ERAS · QTTB · VERV · GOSS · OMIC · UNBX · CERO BEAM · RAPP · ERAS · VERV · GOSS · OMIC · QTTB · UNBX · CERO
2025-Q1 89% 89% 89% BEAM · RAPP · ERAS · VERV · GOSS · OMIC · QTTB · UNBX · CERO BEAM · MAZE · RAPP · ERAS · VERV · GOSS · UNBX · QTTB · CERO
2025-Q2 89% 80% 84% BEAM · MAZE · RAPP · ERAS · VERV · GOSS · UNBX · QTTB · CERO BEAM · VIR · MAZE · RAPP · VERV · LYEL · ERAS · GOSS · QTTB · UNBX
2025-Q3 80% 89% 84% BEAM · VIR · MAZE · RAPP · VERV · LYEL · ERAS · GOSS · QTTB · UNBX RAPP · BEAM · MAZE · VIR · LYEL · ERAS · GOSS · QTTB · CERO
2025-Q4 89% 89% 89% BEAM · RAPP · MAZE · VIR · LYEL · ERAS · GOSS · QTTB · CERO MAZE · BEAM · RAPP · LYEL · VIR · ERAS · GOSS · TXG · QTTB
2026-Q1 100% 90% 95% MAZE · BEAM · RAPP · LYEL · VIR · ERAS · GOSS · TXG · QTTB MAZE · RAPP · VIR · ERAS · BEAM · LYEL · GENB · TXG · GOSS · QTTB
2026-Q2 ★ 80% 80% 80% MAZE · RAPP · VIR · ERAS · BEAM · LYEL · GENB · TXG · GOSS · QTTB PBLS · BEAM · RAPP · SPTX · ERAS · VIR · MAZE · LYEL · GENB · TXG

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did ARCH Venture Management, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, ARCH Venture Management, LLC reported 12 equity positions worth $1.10B in aggregate; its largest disclosed positions were PBLS ($175.52M), BEAM ($155.77M), RAPP ($155.38M).

How large is ARCH Venture Management, LLC's portfolio?

ARCH Venture Management, LLC reported $1.10B of long equity holdings across 12 positions as of 2026-Q2. Top-10 holdings account for 99.3% of reported value.

What is ARCH Venture Management, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/arch-venture-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →